Nippon Shinyaku Co., Ltd., founded in Kyoto, Japan, in 1911, operates globally as a developer, manufacturer, and distributor of pharmaceutical products and functional foods. The company is organized into two primary divisions: Pharmaceuticals and Functional Food. Within its Pharmaceutical division, Nippon Shinyaku offers an extensive range of medications to markets across Japan, Switzerland, and other international territories. These therapeutic solutions address diverse medical challenges such as urological disorders, inflammatory and allergic conditions, hematologic malignancies, cardiovascular and metabolic diseases, and gastrointestinal ailments. Key pharmaceutical offerings include Zalutia and Eviprostat for benign prostatic urinary issues; Bladderon for frequent urination; Estracyt for prostate cancer; and Cialis for erectile dysfunction. Its oncology and hematology portfolio further encompasses Vidaza for myelodysplastic syndrome; Cylocide for solid tumors and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva, a humanized anti-CD20 monoclonal antibody; Defiterio for sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. The company also provides Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler for allergic rhinitis; Azunol Gargle liquid, an azulene-based gargling solution; Isobide for oral osmotic diuresis and Meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for the management of cancer and chronic pain. Beyond its existing product lines, Nippon Shinyaku actively invests in the research, development, and commercialization of new treatments within gynecology, otorhinolaryngology, and orthopedics. The Functional Food segment delivers a variety of health-oriented products, including health food ingredients, preservatives, protein preparations, supplements, and a selection of spices and condiments.
—
Nippon Shinyaku Co., Ltd., founded in Kyoto, Japan, in 1911, operates globally as a developer, manufacturer, and distributor of pharmaceutical products and functional foods. The company is organized into two primary divisions: Pharmaceuticals and Functional Food. Within its Pharmaceutical division, Nippon Shinyaku offers an extensive range of medications to markets across Japan, Switzerland, and other international territories. These therapeutic solutions address diverse medical challenges such as urological disorders, inflammatory and allergic conditions, hematologic malignancies, cardiovascular and metabolic diseases, and gastrointestinal ailments. Key pharmaceutical offerings include Zalutia and Eviprostat for benign prostatic urinary issues; Bladderon for frequent urination; Estracyt for prostate cancer; and Cialis for erectile dysfunction. Its oncology and hematology portfolio further encompasses Vidaza for myelodysplastic syndrome; Cylocide for solid tumors and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva, a humanized anti-CD20 monoclonal antibody; Defiterio for sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. The company also provides Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler for allergic rhinitis; Azunol Gargle liquid, an azulene-based gargling solution; Isobide for oral osmotic diuresis and Meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for the management of cancer and chronic pain. Beyond its existing product lines, Nippon Shinyaku actively invests in the research, development, and commercialization of new treatments within gynecology, otorhinolaryngology, and orthopedics. The Functional Food segment delivers a variety of health-oriented products, including health food ingredients, preservatives, protein preparations, supplements, and a selection of spices and condiments.
—
Daily adjusted close
Nippon Shinyaku Co., Ltd., founded in Kyoto, Japan, in 1911, operates globally as a developer, manufacturer, and distributor of pharmaceutical products and functional foods. The company is organized into two primary divisions: Pharmaceuticals and Functional Food. Within its Pharmaceutical division, Nippon Shinyaku offers an extensive range of medications to markets across Japan, Switzerland, and other international territories. These therapeutic solutions address diverse medical challenges such as urological disorders, inflammatory and allergic conditions, hematologic malignancies, cardiovascular and metabolic diseases, and gastrointestinal ailments. Key pharmaceutical offerings include Zalutia and Eviprostat for benign prostatic urinary issues; Bladderon for frequent urination; Estracyt for prostate cancer; and Cialis for erectile dysfunction. Its oncology and hematology portfolio further encompasses Vidaza for myelodysplastic syndrome; Cylocide for solid tumors and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva, a humanized anti-CD20 monoclonal antibody; Defiterio for sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. The company also provides Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler for allergic rhinitis; Azunol Gargle liquid, an azulene-based gargling solution; Isobide for oral osmotic diuresis and Meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for the management of cancer and chronic pain. Beyond its existing product lines, Nippon Shinyaku actively invests in the research, development, and commercialization of new treatments within gynecology, otorhinolaryngology, and orthopedics. The Functional Food segment delivers a variety of health-oriented products, including health food ingredients, preservatives, protein preparations, supplements, and a selection of spices and condiments.